139481-44-0

• 常用中文名：甲酯C6
• 常用英文名：Methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
• CAS号：139481-44-0
• 分子式：C₂₅H₂₁N₃O₃
• 分子量：411.453
• 发布时间：2018-05-10 08:00:00
• 更新时间：2026-07-01 17:00:59

名称

• 中文名: 1-[(2'-氰基联苯-4-基)甲基]-2-乙氧基-1H-苯并咪唑-7-甲酸甲酯
• 英文名: Methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
• 中文别名: 1-[(2'-氰基联苯-4-基)甲基]-2-乙氧基-苯并咪唑-7-羧酸甲酯; 阿齐沙坦杂质27; 坎地沙坦脂中间体; 阿齐沙坦中间体甲酯; 2-乙氧基-1-[[(2'-氰基联苯-4-取代)甲基]苯并咪唑]-7-羧酸甲酯; 坎地沙坦中间体; 坎地沙坦酯中间体(甲酯C6); 1-[(2'-氰基联苯-4-基)甲基]-2-乙氧基-1H-苯并咪唑-7-甲酸甲酯(坎地沙坦酯中间体); 坎地沙坦酯中间体C6甲酯; 2-乙氧基-1-(2'-氰基联苯-4-基)甲基-1H-苯并[D]咪唑-7-甲酸甲酯; 阿齐沙坦杂质S对照品; 阿齐沙坦-A01; 1-[(2'-氰基联苯-4-基)甲基]-2-乙氧基-1H-苯; 氰基联苯-4-基)甲基]-2-乙氧基-1H-苯并咪唑-7-甲酸甲酯; 阿齐沙坦中间体(甲酯 C6); 阿齐沙坦SM01; 阿齐沙坦中间体B; 坎地化合物(甲酯); 甲基2-乙氧基-1-[(2'-氰基苯基-4-基)-甲基]-1HBENZIMIDAZOLE-7-羧酸酯; 阿齐沙坦杂质S; 坎地沙坦酯中间体; 坎地沙坦中间体(甲酯C6); 坎地沙坦脂; 氰基联苯-4-基)甲基]-2-乙氧基-1H-苯并咪唑-7-甲酸甲酯 中间体; 阿奇沙坦杂质31; 甲酯环合物; 2-乙氧基-1-[[(2-腈基连苯-4-取代)甲基]苯并咪唑]-7-羧酸甲酯; 坎地沙特; 2-乙氧基-1-[[(2'-氰基联苯-4-取代)甲基]苯并咪唑]-7-羧酸甲酯,坎地沙坦酯/阿奇沙坦中间体; 阿齐沙坦INT A 阿齐沙坦-A01; 阿齐沙坦杂质76; 坎地沙坦脂杂质1; 1-[(2'-氰基-[1,1'-联苯]-4-基)甲基]-2-乙氧基-1H-苯并[D]咪唑-7-甲酸甲酯; C6-甲酯; 坎地沙坦C6甲酯; 1-((2'-氰基-[1,1'-联苯]-4-基)甲基)-2-乙氧基-1H-苯并[D]咪唑-7-羧酸甲酯; 1-[[(2'-氰基联苯基)-4-基]甲基]-2-乙氧基苯并咪唑-7-羧酸甲酯; 2-乙氧基-1-[[(2'-氰基联苯-4-取代)甲基]苯; 阿齐沙坦杂质 21; E 甲酯 C6
• 英文别名: Azilstan Impurity 27; Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate; Azilstan & Candestan Cilexetil intermediates; Azilstan MedoxoMil InterMediate; 1-[(2´; Methyl 1-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-cboxylate; 1-[(2'-Cyano-1,1'-biphenyl-4-yl)Methyl]-2-ethoxy-7-benziMidazolecboxylic Acid Methyl Ester; Azilstan Impurity 21; Methyl 1-((2'-cyanobiphenyl-4-yl)Methyl)-2-ethoxy-1H-benzo[d]iMidazole-7-cboxylate; T56 BN DNJ B1R DR BCN&& CO2 IVO1; ethyl 3-((2'-cbamoyl-[1,1'-biphenyl]-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-cboxylate; 1-[(2'-Cyano-[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-cboxylic Acid Methyl Ester; methyl 3-[[4-(2-cyanophenyl)phenyl]methyl]-2-ethoxybenzimidazole-4-carboxylate; Methyl1-[(2’cynobiphenyl-4-yl)methyl]-2-ethoxybenzimidazole-7-cboxylate; cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-cboxylate; Methyl 1-[(2´; Methyl 1-(2'-cyanobiphenyl-4-yl)methyl-2-ethoxy-1H-benzodimidazol-7-cboxylate; 1-[(2'-Cyano[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-cboxylicacidmethylester; 1H-Benzimidazole-7-carboxylic acid, 1-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-, methyl ester; Candestan ester intermediate (methyl C6); Azilstan Nitrile Methyl Ester; Azilstan interMediate B; (Z)-Methyl-2-ethoxy-1-((2'-(N'-hydroxycbamimidoyl)biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7- cboxylate (Intermediate of Azilstan); 1-(2-cyanobiphenyl-4-yl-methyl)- 2-ethoxybenzimidazole-7-cboxylic acid ethyl ester; Azilstan Impurity 1 methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl) -2-ethoxy-1H-benzo[d]imidazole-7-cboxylate; Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-Ethoxy-1H-Benzimidazole-7-Cboxylate [CDS-7]; Methyl 2-ethoxy-1-[(2'-cyanobiphenyl-4-yl)-methyl]-1Hbenzimidazole-7-cboxylate; 1-[(2′-Cyano-1,1′-biphenyl-4-yl)methyl]-2-ethoxy-7-benzimidazolecboxylic acid methyl ester; Candestan (C6) methyl ester intermediates; Azilstan interMediate; 3-[[4-(2-cyanophenyl)phenyl]methyl]-2-ethoxy-4-benzimidazolecboxylic acid methyl ester; Methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-2- ethoxy-1ethyl)-2-H-benzo[d]imidazole-7-cboxylate; Methyl1-[(2'cynobiphenyl-4-yl)methyl]-2-ethoxybenzimidazole-7-cboxylatedine-3-cboxylate; 3-[(2'-Cyanobiphenyl-4-yl)Methyl]-2-ethoxy-3H-benziMidazole-4-cboxylic Acid Methyl Ester; Azilstan-19; 1-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-, methyl ester; Methyl 3-((2'-cyanobiphenyl-4-yl) methyl)-2-ethoxy-3H-benzo [d]imidazole-4-cboxylate; Azilstan impurity 20/Methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-cboxylate; 1H-benzimidazole-7-carboxylicacid,1-[(2-cyano-[1,1’-biphenyl]-4-yl)methyl]-2-ethoxy-,methyl ester; Methyl 1-[(2'-Cyanobiphenyl-4-yl) Methyl]-2-Ethoxy-1H-enzimidazole-7-Cboxylate; methyl 1-((2'-cyano-[1,1'-biphenyl]; METHYL 1-(2'-CYANOBIPHENYL-4-YL)METHYL-2-ETHOXY BENZIMIDAZOLE-7-CARBOXYLATE(EBC-II); IH-BENZIMIDAZOLE-7-CBOXXYLIC ACID,1-((2'-CYANO(1,1-BIPHENYL)-4-YL)METHYL)-2-ETHOXY-ETHYL ESTER; Methyl1-[(2'-cyanobiphenyl-4-yl)Methyl]-2-ethoxy-benziMidazole-7-cboxylate; Methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-cboxylate; Methyl 1-[(2'-cyano-4-biphenylyl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate; METHYL 1-(2'-CYANOBIPHENYL-4-YL)METHYL-2-ETHOXY BENZIMIDAZOLE-7-CBOXYLATE(EBC-II); Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-cboxylate(C6 methylester); 1-[(2’-Cyano-1,1’-biphenyl-4-yl)methyl]-2-ethoxy-7-benzimidazolecboxylic Acid Methyl Ester; Methyl1-[(2'-cyanobiphenyl-4-yl)Methyl]-2-ethoxy-1H-benziMidazole-7-cboxylat; 1-[(2'-Cyanobiphenyl-4-yl)Methyl]-2-ethoxy-1H-benzo[d]iMidazole-7-cboxylic acid Methyl ester; Azilstan Impurity 31; Methyl 1-[(2'; Azilstan Impurity 76; 1H-BENZIMIDAZOLE-7-CBOXYLICACID, 1-[(2'-CYANO[1,1'-BIPHENYL]-4-YL)METHYL]-2-ETHOXY-METHYLESTER; Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-cboxylate; Methyl 1-[(2'-Cyanobiphenyl-4-yl)Methyl]-2-ethoxybenziMidazole-7-cbo; Azilstan Impurity S; 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-cboxylate; MeEthyl-2-ethoxy-1-[[(2'-cyanobiphenyl-4-yl)Methyl]benziMidazole]-7 -cboxylate; CANDESTAN INTERMEDIATE(METHYL ESTER C6)

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 630.4±65.0 °C at 760 mmHg
• 熔点: 168 °C
• 分子式: C₂₅H₂₁N₃O₃
• 分子量: 411.453
• 闪点: 335.1±34.3 °C
• 精确质量: 411.158295
• PSA: 77.14000
• LogP: 5.45
• 外观性状: 固体;White to Orange to Green powder to crystal
• 蒸汽压: 0.0±1.8 mmHg at 25°C
• 折射率: 1.619
• 储存条件: 存放于惰性气体之中;避免空气

安全

• 危害码 (欧洲): Xi
• 海关编码: 2933990090

合成路线

78-09-1 136304-78-4 ~93% 139481-44-0

文献：Kubo, Keiji; Kohara, Yasuhisa; Imamiya, Eiko; Sugiura, Yoshihiro; Inada, Yoshiyuki; et al. Journal of Medicinal Chemistry, 1993 , vol. 36, # 15 p. 2182 - 2195

150058-27-8 114772-54-2 ~% 139481-44-0

文献：WO2006/15134 A1, ; Page/Page column 16; 21-22 ;

21606-04-2 ~% 139481-44-0

文献：Journal of Medicinal Chemistry, , vol. 36, # 15 p. 2182 - 2195

73833-13-3 ~% 139481-44-0

文献：Journal of Medicinal Chemistry, , vol. 36, # 15 p. 2182 - 2195

603-11-2 ~% 139481-44-0

文献：Journal of Medicinal Chemistry, , vol. 36, # 15 p. 2182 - 2195

57113-90-3 ~% 139481-44-0

文献：Journal of Medicinal Chemistry, , vol. 36, # 15 p. 2182 - 2195

856414-36-3 ~% 139481-44-0

文献：Journal of Medicinal Chemistry, , vol. 36, # 15 p. 2182 - 2195

139481-38-2 ~% 139481-44-0

文献：Journal of Medicinal Chemistry, , vol. 36, # 15 p. 2182 - 2195

139481-28-0 ~% 139481-44-0

文献：Journal of Medicinal Chemistry, , vol. 36, # 15 p. 2182 - 2195

上下游产品

上游产品  10
78-09-1 136304-78-4 150058-27-8 114772-54-2
21606-04-2 73833-13-3 603-11-2 57113-90-3
856414-36-3 139481-38-2
下游产品  7
863031-21-4 139481-59-7 139481-69-9 147403-03-0
147403-52-9 147403-65-4 139481-33-7

海关

海关编码	2933990090
中文概述	2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%